Drugs / SCH 39641
SCH 39641
also known as
MK-3641 · Ragwitek · Short and Tall Ragweed Mix · Short ragweed pollen allergen extract
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03038971 | Mar → Apr 2017 | allergic rhinitis, conjunctivitis | Woodmont Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00978029 | Nov 2009 → Feb 2010 | conjunctivitis, ragweed sensitivity, rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00783198 | Sep 2009 → May 2011 | allergic rhinitis, conjunctivitis | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02676765 | Jun 2016 → Jan 2018 | — | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 3 | NCT02478398 | Jul 2015 → Nov 2018 | seasonal allergic rhinitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01469182 | Nov 2011 → Apr 2012 | ragweed sensitivity | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02256553 | Oct 2014 → Feb 2015 | seasonal allergic rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-05-15 | ALK-Abelló A/S | ALK's partner for North America, Merck, announces launch of RAGWITEK™ in Canada alk.net ↗ |
| 2014-04-17 | ALK-Abelló A/S | ALK announces FDA approval for Merck's ragweed sublingual allergy immunotherapy tablet RAGWITEK® alk.net ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCH 39641 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00783198 ↗ |
| Known as | MK-3641 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02256553 ↗ |
| Known as | Ragwitek | “Ragwitek” NCT02676765 ↗ |
| Known as | Short and Tall Ragweed Mix | “Concentration 1: Short and Tall Ragweed Mix” NCT03038971 ↗ |
| Known as | Short ragweed pollen allergen extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02478398 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Short ragweed pollen allergen extract” NCT02478398 ↗ |
| Route | Other | “One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.” NCT02478398 ↗ |